patients who presented with advanced or recurrent Hodgkin's disease and were free of disease after six courses of chemotherapy with mustine, vinblastine, procarbazine, and prednisone (MVPP) were allocated at random to one of two regimens of maintenance treatment: either intermittent treatment with vinblastine and procarbazine or intermittent treatment with MVPP. After a median follow-up period of nearly five years there was no significant difference between the two groups in either the rate of relapse or death rate. Six of the 55 patients given the two-drug regimen died compared with 10 of the 53 given the four-drug regimen. The four-drug regimen required hospital attendance and was less agreeable than the two-drug regimen.
Introduction
The usefulness of maintenance chemotherapy in advanced Hodgkin's disease remains uncertain, but in 1970 it was generally considered to be desirable. At that time the Medical Research Council instituted a randomised clinical trial to compare a two-drug regimen of maintenance chemotherapy (vinblastine and procarbazine (VP)) with a regimen using four drugs (mustine, vinblastine, procarbazine, and prednisone (MVPP)), one of which (mustine) had to be given by intravenous drip and sometimes produced severe nausea and vomiting. We report the results of the trial.
Patients and methods
The trial was restricted to patients with advanced or recurrent Hodgkin's disease. Patients were eligible for entry if they had not already received chemotherapy and presented either with advanced disease (stage IIIB, IVA, or IVB) or with relapse in an area that had been treated with radiotherapy. All patients were treated initially with six courses of MVPP, similar to the regimen described.1 A course consisted of mustine (6 mg/M2) and vinblastine (6 mg/M2) given intravenously on days 1 and 8 and procarbazine (100 mg/M2) and prednisone (40 mg) taken by mouth on days 1 to 14 inclusive. A gap of four weeks was left between courses. Sometimes the drug doses had to be reduced, particularly in the case of mustine, because of marrow suppression.
Hodgkin's disease was confirmed histologically and classified as described. 2 1977; the remaining patient emigrated 57 months after randomisation (to VP). All patients were followed up for at least two years, the median follow-up period being 4 years 11 months.
Results
Of the 108 patients, 55 were allocated to treatment with the two-drug (VP) regimen and 53 to treatment with the four-drug (MVPP) regimen. There was no appreciable difference between the groups in the distribution of factors of possible prognostic importance (table I) . In the analysis 10 patients who either relapsed before receiving their first course of treatment or received a different treatment from the one allocated were included in the group to which they had initially been randomised (see footnote to table I). For analysis all these patients are included in treatment group to which they were allocated at random. Figure 1 gives the actuarial estimates of the proportions of patients alive at different times after randomisation to the two treatment groups. Six of the 55 patients allocated to the VP regimen and 10 of the 53 allocated to the MVPP regimen died. This difference is not significant and there was no convincing evidence of any difference in survival times between the two groups. Actuarial estimates of the proportions of patients surviving for at least five years after randomisation were 88% with the two-drug regimen (950% confidence interval 77-90%) and 80% with the four-drug regimen (95% confidence interval 66-890'). Of the 16 patients who died, 14 died of Hodgkin's disease and two (both in the MVPP group) of acute myeloblastic leukaemia, one at 21 months and the other 48 months after randomisation. Fig 2 shows the durations of remission after randomisation. Eighteen patients relapsed in the VP group and 16 in the MVPP group, and again there was no material difference in the durations of remission between the two groups. Steps indicate when patients died. Vertical bars indicate when patients who were still alive were last followed up. Numbers of deaths given in parentheses. *Excludes one patient who died without record of relapse.
Discussion
There was no evidence of any benefit associated with fourdrug maintenance chemotherapy as compared with two-drug chemotherapy among patients with advanced or recurrent Hodgkin's disease who achieved remission after six courses of combination chemotherapy. The initial results of one study suggested that some form of maintenance chemotherapy is of value,4 but longer follow-up of the patients failed to confirm this5; and another study failed to show any benefit associated with maintenance treatment. 6 Our results therefore need to be interpreted in the light of the possibility that maintenance chemotherapy may not be necessary at all. If a decision is made to offer patients maintenance treatment the simpler, two-drug regimen seems to be preferable as it does not require hospital admission for administration.
Because of the small size of this trial the results need to be interpreted with caution. The same reservation applies to the two American studies mentioned above. One of these included 75 patients4 and the other 57,6 and neither offered conclusive evidence for or against maintenance chemotherapy. In our trial the difference between the proportions of patients expected to survive five or more years after randomisation was only 80o
(88",, in the VP group and 800,, in the MVPP group surviving five years), and the 950, confidence interval on this difference 6 o to 230O) was wide enough to include the possibility that MVPP might be better than VP.
All the patients in the trial were followed up for at least two years, and the rate of first relapse among patients who had not relapsed by that time was low and seemed likely to remain so (table II) . Patients who did relapse, however, experienced a high mortality, half of them dying within three years later ( fig 3) ; and only one patient in the study died without record of a relapse. Any difference in mortality between the two treatment groups in the next few years is therefore likely to occur only among patients who had already relapsed. In view of the low relapse rate after the first two years of the trial mortality will probably remain low in patients who did not have a relapse, and as there were only 18 patients who did relapse and were still alive by July 1977 (12 in the VP group, 6 in the MVPP group) large differences in survival between the two treatments will probably not emerge in the next few years.
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A possible argument for use of the VP regimen is that since drug resistance might be less with two drugs than with four, relapse might be easier to treat, and our results suggest that this may be so; patients relapsing during treatment with VP tended to survive longer than those relapsing in the MVPP group. The difference was quite pronounced but the numbers were small and it was not statistically significant (fig 3) .
Of the 16 patients who died, two died of myeloblastic leukaemia. This was highly significantly (P <0-001) more than would be expected (0 03) if the 108 patients in the trial had experienced the same mortality rates from leukaemia as the general population of England and Wales. Both deaths occurred in patients with advanced Hodgkin's disease (stages IIIB and IVB) who had received no chemotherapy or radiotherapy before the six courses of MVPP which preceded randomisation. Inducing leukaemia is a recognised complication of treating Hodgkin's disease with intensive chemotherapy,7 8 a risk that appears to be even greater in patients who have also received radiotherapy. The average yearly risk of dying from leukaemia among patients in our trial was about 0A4% after randomisation, which is similar to that reported by Coleman et al.7 There is no doubt that intensive chemotherapy has prolonged the lives of patients with advanced or recurrent Hodgkin's disease, and this outweighs the risk of leukaemia associated with treatment. That both patients who died of leukaemia received the four-drug maintenance regimen may well have happened by chance, but it seems reasonable to suppose that the risk of leukaemia may increase with the amount of chemotherapy given, which is an additional argument against the use of four-drug maintenance treatment.
Patients were entered into the study only if they were in clinical remission at the time of randomisation, which was three months after completing six courses of chemotherapy. Survival and remission rates therefore relate only to patients who achieved remission. Since patients were not uniformly notified to the trial co-ordinating centre at the time of first diagnosis we cannot give the survival or disease-free periods of the original population ofpatients. Nevertheless, of the patients in the present study whose remission was successfully induced with MVPP, 84% (95o% confidence interval 76-90 / ) were alive 5 years after randomisation to the two maintenance regimens. This and the observation that the relapse rates and death rates of patients in the trial declined significantly with time after randomisation suggest that a high proportion of patients who did not relapse within two years of starting maintenance treatment may have been "cured."
Data from the participating centres were collected by Mrs Catherine Harwood. The working party was disbanded in December 1975. Introduction Prostatic adenomas of small or average size may be removed by adequately trained staff as safely and effectively by the transurethral route as by open operation.' The superiority of transurethral resection in terms of the length of stay in hospital and degree of discomfort to the patient is a strong argument in favour of training and employing more specialist urologists.2 Despite the increasing popularity of transurethral resection, however, particularly large prostates are still assumed to be better dealt with by an open operation, partly because of the tedium and difficulty of doing a long resection but also for fear of greater complications postoperatively.
To see whether larger prostates may be equally well resected we analysed a consecutive series of 102 transurethral resections of benign prostates weighing 40 g or more. 
Patients and methods
We studied 102 patients-that is, all those in whom one of us (RHW) resected 40 g or more during April 1971 to March 1976. Their mean age was 70 years; table I shows the age distribution. The patients were graded according to their preoperative fitness as follows.' Grade 1: fit men aged under 70 years with no known cardiovascular or respiratory disease and not diabetic. Grade 2: men aged 71-80 years and younger men with diabetes, hypertension, or chronic lung disease; also those with a history of myocardial infarction or cerebrovascular accident more than six months previously. Grade 3: men aged over 80 years or very unfit, and those with recent myocardial infarction or cerebrovascular accident. Table II shows the distribution of the patients between these three categories. Most of the operations in this series were performed under general anaesthesia; a few patients had a spinal anaesthetic. The instrument used was a 26F Thackray or Storz loop resectoscope; if the urethra was tight for this an Otis internal urethrotomy was performed. In all cases we believed that all adenomatous prostatic tissue had been removed.
Most of the resections were of prostates weighing 40-60 g, but several were considerably larger. Table III shows the distribution of   TABLE III 
